ANL: Bathi resik saben saham (EPS TTM) Adlai Nortye Ltd.

Adlai Nortye Ltd. (ANL) is actively developing its pipeline of drugs for solid tumors as it prepares to bring palitosert to market. The change in the rolling annual EPS reflects the impact of these achievements, with -0.54 serving as the parameter's baseline value. Growth is supported by laboratory robotization and Big Data, although global expansion is complicated by geopolitical risks and fierce competition within the biopharmaceutical sector.
Adlai Nortye Limited - rincian analitis lan metrik utama (ANL)

To isolate the fundamental stability of Adlai Nortye Ltd. (ANL) from market noise, it is necessary to evaluate the real efficiency of capital. This indicator measures net income allocated per ordinary share over a trailing twelve-month period. By analyzing the TTM earnings per share, an investor determines the business's ability to generate returns. The stability of this metric is supported by a diversified portfolio of oncology drugs, while access to the Asian market provides a long-term foundation for profit growth.